These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 32473373)
1. Optimization of the manufacturing process of a complex amphotericin B liposomal formulation using quality by design approach. Liu H; Rivnay B; Avery K; Myung JH; Kozak D; Landrau N; Nivorozhkin A; Ashraf M; Yoon S Int J Pharm; 2020 Jul; 585():119473. PubMed ID: 32473373 [TBL] [Abstract][Full Text] [Related]
2. Critical process parameters in manufacturing of liposomal formulations of amphotericin B. Rivnay B; Wakim J; Avery K; Petrochenko P; Myung JH; Kozak D; Yoon S; Landrau N; Nivorozhkin A Int J Pharm; 2019 Jun; 565():447-457. PubMed ID: 31071418 [TBL] [Abstract][Full Text] [Related]
3. A step forward towards the development of stable freeze-dried liposomes: a quality by design approach (QbD). Sylvester B; Porfire A; Achim M; Rus L; Tomuţă I Drug Dev Ind Pharm; 2018 Mar; 44(3):385-397. PubMed ID: 29098869 [TBL] [Abstract][Full Text] [Related]
4. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method. Kovács A; Berkó S; Csányi E; Csóka I Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940 [TBL] [Abstract][Full Text] [Related]
5. Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process. Ingvarsson PT; Yang M; Mulvad H; Nielsen HM; Rantanen J; Foged C Pharm Res; 2013 Nov; 30(11):2772-84. PubMed ID: 23794038 [TBL] [Abstract][Full Text] [Related]
6. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209 [TBL] [Abstract][Full Text] [Related]
7. Optimizing Process Parameters for Controlled Drug Delivery: A Quality by Design (QbD) Approach in Naltrexone Microspheres. Reddy PL; Shanmugasundaram S AAPS PharmSciTech; 2024 May; 25(5):105. PubMed ID: 38724807 [TBL] [Abstract][Full Text] [Related]
8. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. Nekkanti V; Muniyappan T; Karatgi P; Hari MS; Marella S; Pillai R Drug Dev Ind Pharm; 2009 Oct; 35(10):1219-29. PubMed ID: 19555246 [TBL] [Abstract][Full Text] [Related]
9. QbD for pediatric oral lyophilisates development: risk assessment followed by screening and optimization. Casian T; Iurian S; Bogdan C; Rus L; Moldovan M; Tomuta I Drug Dev Ind Pharm; 2017 Dec; 43(12):1932-1944. PubMed ID: 28748713 [TBL] [Abstract][Full Text] [Related]
11. Critical Tools in Tableting Research: Using Compaction Simulator and Quality by Design (QbD) to Evaluate Lubricants' Effect in Direct Compressible Formulation. Jiwa N; Ozalp Y; Yegen G; Aksu B AAPS PharmSciTech; 2021 May; 22(4):151. PubMed ID: 33977355 [TBL] [Abstract][Full Text] [Related]
12. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques. Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242 [TBL] [Abstract][Full Text] [Related]
13. Design of experiments (DoE) in pharmaceutical development. N Politis S; Colombo P; Colombo G; M Rekkas D Drug Dev Ind Pharm; 2017 Jun; 43(6):889-901. PubMed ID: 28166428 [TBL] [Abstract][Full Text] [Related]
14. Quality by Design: Concept to Applications. Swain S; Parhi R; Jena BR; Babu SM Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238 [TBL] [Abstract][Full Text] [Related]
15. Managing API raw material variability in a continuous manufacturing line - Prediction of process robustness. Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Vervaet C; De Beer T Int J Pharm; 2019 Oct; 569():118525. PubMed ID: 31319146 [TBL] [Abstract][Full Text] [Related]
17. Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films. Visser JC; Dohmen WM; Hinrichs WL; Breitkreutz J; Frijlink HW; Woerdenbag HJ Int J Pharm; 2015 May; 485(1-2):70-6. PubMed ID: 25746737 [TBL] [Abstract][Full Text] [Related]
18. An Experimental-Based Approach to Construct the Process Design Space of a Freeze-Drying Process: An Effective Tool to Design an Optimum and Robust Freeze-Drying Process for Pharmaceuticals. Assegehegn G; Brito-de la Fuente E; Franco JM; Gallegos C J Pharm Sci; 2020 Jan; 109(1):785-796. PubMed ID: 31288035 [TBL] [Abstract][Full Text] [Related]
19. Use of a temperature ramp approach (TRA) to design an optimum and robust freeze-drying process for pharmaceutical formulations. Assegehegn G; Brito-de la Fuente E; Franco JM; Gallegos C Int J Pharm; 2020 Mar; 578():119116. PubMed ID: 32027958 [TBL] [Abstract][Full Text] [Related]
20. A quality by design approach to understand formulation and process variability in pharmaceutical melt extrusion processes. Patwardhan K; Asgarzadeh F; Dassinger T; Albers J; Repka MA J Pharm Pharmacol; 2015 May; 67(5):673-84. PubMed ID: 25615235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]